Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022
Jason Robert C Singson, Pam Daily Kirley, Huong Pham, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 27, pp. 878-884
Open Access | Times Cited: 82

Showing 26-50 of 82 citing articles:

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe
Maria R. Farcet, Michael Karbiener, Simone Knotzer, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1396-1400
Open Access | Times Cited: 11
Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
Angalee Nadesalingam, Diego Cantoni, Ernest T. Aguinam, et al.
The Lancet Microbe (2022) Vol. 4, Iss. 2, pp. e58-e59
Open Access | Times Cited: 11
Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study
Morgan Birabaharan, Eddie Hill, Maedha Begur, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 8, pp. 1500-1503
Open Access | Times Cited: 11
The unmet need for COVID-19 treatment in immunocompromised patients
Alessandra D’Abramo, Serena Vita, Emanuele Nicastri
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
Harvey W. Kaufman, William A. Meyer, Nigel J. Clarke, et al.
Population Health Management (2023) Vol. 26, Iss. 1, pp. 29-36
Open Access | Times Cited: 6
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews
Thuan Tong Tan, Heng Joo Ng, Barnaby Edward Young, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 341-365
Open Access | Times Cited: 6
COVID-19 Prevention in Solid Organ Transplant Recipients
Maria Tsikala Vafea, Ghady Haidar
Infectious Disease Clinics of North America (2023) Vol. 37, Iss. 3, pp. 459-473
Open Access | Times Cited: 6
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants
Hannes Lindahl, Puran Chen, Mikael Åberg, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1075-1082
Open Access | Times Cited: 6
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G. Ison, Myra W. Popejoy, Nikolay Evgeniev, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 6
Development of COVID-19 vaccine policy — United States, 2020–2023
Sara E. Oliver, Megan Wallace, Evelyn Twentyman, et al.
Vaccine (2023), pp. 125512-125512
Open Access | Times Cited: 6
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE Framework
Xuan Wang, Katrin Haeussler, Anne Spellman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases
Yan Geng, Yong Fan, Xuerong Deng, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 4, pp. 1039-1053
Open Access | Times Cited: 5
ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review
Alexandre Gaudet, Louis Kreitmann, Saad Nseir
Antibiotics (2023) Vol. 12, Iss. 9, pp. 1464-1464
Open Access | Times Cited: 5
Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations
Elizabeth Titova, Veronica W. Kan, Tara Lozy, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 3
Open Access | Times Cited: 1
Too Many Deaths, Too Many Left Behind: A People's External Review of the U.S. Centers for Disease Control and Prevention's COVID-19 Pandemic Response
Lara Jirmanus, Rita M Valenti, E. Schwartzman, et al.
AJPM Focus (2024) Vol. 3, Iss. 4, pp. 100207-100207
Open Access | Times Cited: 1
Perceptions of Telehealth-Based Cancer Support Groups at a Rural Community Oncology Program
Bree Holtz, Katharine M. Mitchell, Deborah Strand, et al.
Journal of Cancer Education (2024) Vol. 39, Iss. 4, pp. 418-425
Closed Access | Times Cited: 1
Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study
Irit Nachtigall, Stefan Kwast, Sven Hohenstein, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 634-634
Open Access | Times Cited: 1
Torquetenovirus from bronchoalveolar lavage fluid as a biomarker for lung infection among immunocompromised hosts
Ziwen Zhu, Yang Wang, Weiwei Ning, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 13-14, pp. 581-591
Closed Access | Times Cited: 1
Convalescent Plasma for Immunocompromised Patients
Shmuel Shoham
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
Cameron R. Wolfe, Jonathan Cohen, Kathryn Mahoney, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Association of SARS-CoV-2 Nucleocapsid Protein Mutations with Patient Demographic and Clinical Characteristics during the Delta and Omicron Waves
Feda A. Alsuwairi, Asma N. Alsaleh, Madain S. Alsanea, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes
Harvey W. Kaufman, Stanley Letovsky, William A. Meyer, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 4
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
Areum Shin, Dong Wook Kim, Young‐Eun Kim, et al.
Journal of Korean Medical Science (2023) Vol. 38, Iss. 32
Open Access | Times Cited: 4
The Effectiveness of COVID -19 Vaccine for Immunocompromised Adults During Omicron Predominance
Masoud Mardani
Archives of Clinical Infectious Diseases (2023) Vol. 17, Iss. 6
Open Access | Times Cited: 3
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine
Lila Estephan, Luke Tzu-Chi Liu, Chia-En Lien, et al.
Vaccine (2023) Vol. 41, Iss. 15, pp. 2615-2629
Open Access | Times Cited: 3

Scroll to top